Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation

    January 2023 in “ Hormone and Metabolic Research ”
    Rufaida Wasim, Tarique Jamal Ansari, Mohammed Haris Siddiqui, Farogh Ahsan, Arshiya Shamim, Aditya Singh, Mohammad Shariq, Aamir Anwar, Aquib Rehanullah Siddiqui, Saba Parveen
    Image
    Studysummary This review discusses drug repositioning as a promising strategy for developing treatments for cardiometabolic disorders and reports no new clinical results.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Cardiometabolic disorders (CMD), including insulin resistance, diabetes mellitus, hypertension, obesity, and dyslipidemia, are leading causes of death worldwide, accounting for over 32% of global fatalities each year. However, new drug development for CMDs has been challenging due to high costs and low success rates. As an alternative, drug repositioning, a method dating back to the 1960s, is gaining interest. This involves using existing drugs for new therapeutic indications. The advantage of repositioning is that the safety profile of the drug is already known, reducing the risk of failure due to toxic effects. Additionally, repositioning is less time-consuming and costly than new drug development.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results